Adjusting ph and osmolarity of infusion solutions: what is reasonable?
Understanding pH
Marc Stranz, PharmD
• pH and osmolarity tolerance guidelines, •
Definitions of pH and osmolarity,
pH and osmolarity in vitro data,
pH and osmolarity of common infusions,
Altering pH and osmolarity, and
Pharmacists' perspective on pH and osmolarity.
Scope of this presentation
• Clinical and pharmaceutical aspects of pH
and osmolarity of infusates.
− Damage induced by ions (pH) and osmolarity
rarely occurs as an isolated event.
− Other factors: mechanical, material, duration,
infection, particulate, and chemical
• To prevent or reduce vascular complications,
INS standards recommend that
− Infusions with a pH outside the range of 5 to 9
− an osmolarity greater than 600−
be administered through an access device that
delivers the infusate into a blood vessel with a high rate of blood flow.
• Chemical irritation causes:
− Loss of venous endothelial cells,−
Inflammatory cell infiltration,
Proximal and distal to the catheter tip.
Loss of endothelial cells
Inflammatory cells
Perivascular edema
Review of osmolarity and pH
• Osmosis/osmolality.
− human plasma osmolality is 290 mOsm/L
(285 - 310 mOsm/L).
• Isotonic - Normal Saline
• Hypotonic - ½ Normal Saline
• Hypertonic - Dextrose 5% & Normal Saline
Review of osmolarity and pH
• Osmolality and osmolarity
− Osmolality is defined as the number of milliosmoles
per kilogram of solvent.
− Osmolarity is defined as the number of milliosmoles
per liter of solution.
• Intravenous fluid labeling has osmolarity, but not
required for intravenous admixtures
Review of osmolarity and pH
• Osmolality can be estimated from:
- O smolality = [ (CiEi) X 0.58/1.86] X 1000 where C = grams of
solute per 100ml of solution, E = the sodium chloride equivalent, and (CiEi) = the sum of the products of (C X E) for each solute in the solution.
• NaCl Equivalent Value tables exist for common drugs
- When the sodium chloride equivalents are unknown, the following
equation is used to determine a value for E: E = 17 X (Liso/MW) where Liso is a value that takes into account the nonideal behavior of ionic solution and depends on the nature of the solute and MW is molecular weight. An Liso value of 4.3 is used for disodium salts and a value of 3.4 for all other drugs.
Review of osmolarity and pH
• Osmolarity can be determined from the
• mOsM = wt of substance (g/L) x number of x 1000
molecular wt (g) specie (ion)
• Molecular wt from package insert
• As the concentration of the solute increases, interaction among
solute particles increases and actual osmolar values decrease
when compared to ideal values. The variance can be significant for concentrated solutions.
• Calculated osmolarity 0.9% NaCl =9/58.4x2x1000= 308
• Measured osmolality 0.9% NaCl = 286
Review of osmolarity and pH
− The pH scale runs from 0 to 14−
Logarithmic scale, based on power of 10
1 pH unit change equals a 10-fold change in
H+ ion concentration
− Change from pH 7.35 to pH 7.15 is a 2% drop
in pH but equals a 24% change in H+ ion concentration.
Review of osmolarity and pH
Common acids and bases:
Lemon juice
Rainwater
Neutral 1 x 10-7 7
1 x 10-10 10 Tums® antacid
1 x 10-11 11 Ammonia
1 x 10-12 12
Mineral Lime - Ca(OH)2
1 x 10-13 13
1 x 10-14 14
Review of osmolarity and pH
• Titratable acidity
− increases the phlebitic potential−
a measure of the reservoir of H+ ion in the
− high titratable acidity irritates venous
endothelial cells over a longer distance from the catheter tip
− common to parenteral nutrition
What pH damages cells?
• pH's of 2.3 and 11 have been shown to kill
• As the pH moderates, the cells survive for
a longer time period
• Cell cultures at pH 4 survived for 10
minutes. Same for pH 9?
• pH is logarithmic, so pH 5 to 8 safer?
Mitigating factors
• Buffering systems
− Stabilize the pH−
The bicarbonate system keeps blood pH near
− The time to neutralize the pH is a function of
the strength of the acid or base and the titratable acidity
Mitigating factors
− laminar flow is a layer parallel to but separate from
the surrounding blood flow
− slow diffusion of blood at the contact surface−
cells downstream exposed to the irritating solution.
predominance of damage on the lower part of the
− supports finding that faster infusion rates reduce
phlebitic potential
Laminar Blood Flow
• Laminar flow is
characterized by concentric layers of blood moving in parallel down the length of a blood vessel.
• The highest velocity is
found in the center of the vessel.
• The lowest velocity is
found along the vessel wall.
• Certain infusates produce phlebitic
changes despite being isotonic and pH neutral.
• Drugs can alter endothelial cell
metabolism, cause cell-cycle arrest, inhibit DNA synthesis, and induce inflammatory responses
Macrolides (erythromycin, azithromycin)
Quinolones (ciprofloxacin, levofloxacin)
• Few trials have been
Penicillinase-resistant penicillins
conducted and even fewer
(nafcillin, oxacillin)
drugs have been tested for
Penems (imipenem, meropenem)
direct cytotoxic effects on vascular endothelial cells
• With the exception of some
chemotherapy drugs, toxicity is
concentration dependent
• This validates the use of lower
Antineoplastics (cladribine, mitomycin)
concentrations, slower infusion
Steroids (reversible)
rates, and larger blood vessels.
Cyclosporin (reversible)
Phlebitis in vivo
• Animal data isolates traumatic effect of pH
− Six hour infusions through peripheral vessels: −
pH 4.5 = 100% severe phlebitic changes,
pH 5.9 = mild to moderate phlebitis in 50%,
pH 6.3 = mild damage in 20%, and
pH 6.5 = no significant damage
Phlebitis in vivo
• Animal data isolates traumatic effect of pH
− At pH 6.5, extending infusion duration
produced no additional phlebitis
− At pH 3 to 11, no phlebitic changes when
− At pH 5, infused over 5 hours, 1 hour, or 30
minutes, phlebitis less with faster infusions
Phlebitis in vivo
• Animal data isolates traumatic effect of pH
− No studies of slowing infusions to reduce
− With peripheral parenteral nutrition, pH and
titratable acidity cause phlebitis
− The higher the titratable acidity, the greater
the proximal and distal phlebitic changes
Phlebitis in vivo
• Animal data isolates traumatic effect of pH and
− Tolerance osmolarity of peripheral vessels in animals
⋅ 820 mOsm/kg for 8 hours, ⋅
690 mOsm/kg for 12 hours, and
550 mOsm/kg for 24 hours.
Faster infusion of hypertonic infusates resulted in
greater vein tolerance
Phlebitis in humans
• The exact point at which osmolarity and
pH become a liability in humans is unknown because of the variables involved in that determination
• There is significant interpatient variability
in results of these trials
Phlebitis in humans
• The most cited human study of osmolality-
induced phlebitis found:
− the lowest risk of phlebitis occurred with solution
osmolalities under 450 mOsm/L,
− moderate risk at 450 to 600 mOsm/L and−
highest risk over 600 mOsm/L
Helped establish 600 mOsm/L as the outer limit
of peripheral vein tolerance
Phlebitis in humans
• Human trials measuring the impact of pH
on peripheral veins found:
− neutralizing the pH to 7 - 7.4 significantly
reduced the incidence of phlebitis
· There are no human trials that control for the
phlebitic potential of a range of pH values
· There are ophthalmic trials demonstrating that the
pH range necessary to prevent corneal damage is 6.5 to 8.5
Phlebitis in humans
• The INS pH range of 5 to 9 for peripheral
veins represents clinically significant variances from ideal pH. However, factors such as blood flow, the infusion rate, and patient variability influence pH-induced phlebitis, permitting a more encompassing range of final drug admixture pH values
Measured pH and osmolality
• When plotted by pH and osmolality
− Most drug solutions fall within the pH range of
5 to 9, but many are less than pH 6 and a significant number in the 3-5 range
− Almost all drug solutions osmolalities are
below 500 mOsmol/L
pH Distribution - Infusion Drugs
Number of Drugs
Osmolarity Distribution - Infusion Drugs
Number of Drugs
Modifying pH and osmolality
• Osmolality is not a primary cause of
infusion phlebitis (without peripheral parenteral nutrition)
− If the osmolality is > 400, change the diluent
to sterile water or ½ NS
− Ready-to-Use drugs are usually isotonic−
Co-infusion of drugs with running hydration
solutions will reduce the osmolality of the drug solution
Modifying pH and osmolality
• pH is a primary cause of infusion phlebitis
− The drug pH profile determines the product
⋅ This pH results in optimum stability or solubility⋅
Optimum drug stability is usually found at the
− Manufacturers get as close to pH 7.35 as the
pharmaceutical parameters permit.
Modifying pH and osmolality
• pH is a primary cause of infusion phlebitis
− Dextrose solutions are acidic because
dextrose decomposition increases as the pH rises toward 7
− Saline solutions are stable at a neutral pH, but
are made acidic to enhance drug additive stability.
Modifying pH and osmolality
• pH is a primary cause of phlebitis
− Parenteral nutrition solutions are acidic to enhance
electrolyte solubility. Calcium phosphate precipitation increases as pH increases
− Diluents can increase pH. A drug with a pH of 4.7 in
NS has a pH of 4.9 in D5RL, a pH of 5.0 in D5Plasmalyte 56, and a pH of 5.5 in Sodium Lactate.
• Osmolality of drug solutions is not a
primary concern when considering the overall causes of peripheral phlebitis
• pH is and will remain a significant cause of
phlebitis in peripheral veins. One might call it pHlebitis
• INS standards suggest a range of pH 5 to
9 as peripherally tolerable.
− Animal and human data suggest that a lesser
variance from pH 7.4 causes damage, but the mitigating effect of short duration infusions has not been determined
− Furthermore, one cannot ignore the influence of
cannula material, cannula size, vein size, and vein site upon the effect of pH and osmolarity
• Pharmacists are not necessarily aware of pH
and osmolality data
• Pharmacists use charts, texts, and more often
computer data to decide on dilution, stability, and infusion rates. The addition of pH and osmolality to these sources will assist in identifying candidates for central catheters
Source: http://www.amaconsultoria.com.br/artigos/picc/understanding-ph-and-osmolarity.pdf
Women's History Review The Women's Charter: American Communists and the Equal Rights Amendment debate View full textDownload full text Full access Denise Lynn* Publishing models and article dates explained Published online: 23 Apr 2014 Article Views: 8 Alert me Abstract The American Communist Party (CPUSA) opposed the Equal Rights Amendment (ERA), arguing that it failed to ameliorate class and racial inequality. In 1936 the CPUSA participated in the Women's Charter campaign, an alternative to the ERA crafted to protect labor legislation. This article argues that the Charter campaign and the CPUSA's opposition to the ERA demonstrate class-based visions of equality that amalgamated race and gender into the class struggle and highlights disagreements among women's rights activists about how to define women's equality. These disagreements prevented a unified single-issue women's movement after 1920.
GAIPOS-2318; No of Pages 8 Gait & Posture xxx (2006) xxx–xxx Long-term monitoring of gait in Parkinson's disease Steven T. Moore ,, Hamish G. MacDougall , Jean-Michel Gracies Helen S. Cohen William G. Ondo a Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA b Bobby R. Alford Department of Otolaryngology—Head and Neck Surgery, Baylor College of Medicine, Houston, TX, USA